INTRODUCTION:

Sputnik V:

The manufacturer’s vaccine showed the results of two open-ended studies of the first and second stages that were not randomly selected for the Coronavirus vaccine. The Russian vaccine is based on recombinant adenovirus vectors (rAd26-S and rAd5-S). The manufacturer said the vaccine is safe and stimulates the humoral immunity as well as cellular immune responses by 100% of healthy participants. It is reported that all negative cases were mostly moderate. The most common systemic and local reactions were the presence of pain at the injection site, a slight increase in body temperature from 37 to 38°C, as well as headache, weakness, and muscle and joint pain. In general, these symptoms are typical of vector-dependent recombinant vaccines. According to the manufacturer's report, no serious adverse events were reported during the study. The adverse event profile was not different from that reported in published work for other vector-dependent vaccines.

One in 7 volunteers who received the Russian coronavirus vaccine experienced side effects. The Russian Health Ministry said 14% of volunteers complained of side effects after Sputnik's test. Side effects of the vaccine included weakness and muscle pain. So far infected volunteers have small complaints of these symptoms for a period of 24 hours. They also reported an occasional increase in body temperature. Officials said the symptoms disappear the next day. The final clinical trials of the Russian vaccine started in Moscow earlier in September 2020. Russian Health Minister Mikhail said that more than 300 of the 40,000 volunteers were vaccinated with the next injection. The volunteers were expected to receive a second injection of an adenovirus-based viral vector vaccine within 21 days of the first dose. Russian government officials and party leaders also participated in the trials. In recent days, vaccine developers have begun distributing Sputnik V across Russian states for the third trials. The general public can be vaccinated in late November or early December depending on the government report. Russia has confirmed nearly 1.1 million cases of COVID-19 since the outbreak began 7 months ago. Russia has seen a steady increase of coronavirus cases in last days. A recent study by Russian vaccine developers showed that it was 10% effective at producing antibodies in all 76 participants in early phase trials. Last month, Russian authorities approved the Sputnik V vaccine, despite concerns from the scientific community about its safety. The regulatory agency approved after less than two months of human testing. The decision gives the health authorities the green light for comprehensive vaccination^1-13.

Health experts have raised doubts about its long-term safety and effectiveness. Based on the updated vaccine result, public opinion polls have shown that nearly half of Russians are not planning to receive a coronavirus vaccine at any time. What is expected and what are the results? Nobody knows where this stubborn virus will take us or when it will disappear.

ACKNOWLEDGMENTS:

The author thanks the University of Mosul for approving this work.

CONFLICT OF INTEREST:

The author declares no conflict of interest.

REFERENCES:

1. Logunov D, Dolzhikova I, and Zubkova O. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 2020; Sep.:1-11. https://doi.org/10.1016/S0140-6736(20)31866-3.

2. Turak N. Russia’s potential coronavirus vaccine shows ‘no serious adverse’ effects and creates antibody response: The Lancet study. CNBC. 2020; Sep.: 4. https://www.cnbc.com/2020/09/04/russian-coronavirus-vaccine-shows-no-serious-side-effects-lancet-says.html.

3. Times of India. Controversial Russian coronavirus vaccine shows immune response; no major side-effects reported, shares Lancet study. Etimes. 2020; Sep.:8. https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/controversial-russian-coronavirus-vaccine-shows-immune-response-no-major-side-effects-reported-shares-lancet-study/photostory/77997057.cms.

4. Rokade M, and Khandagate P. Coronavirus disease: A review of a New Threat to Public Health. Asi J Pharm Res. 2020;10(3):241-244. https://doi:10.5958/2231-5691.2020.00042.8.

5. Prathmesh J, Manohar K, Ravina J, Aishwarya S, Shweta. K, and Honmane P. On overview- Corona virus and Hanta virus Disease. 2020;10(3):178-182. https://doi:10.5958/2231-5659.2020.00034.X.

6. Dawood A, Alnori H. Tunicamycin Anticancer Drug May Reliable to Treat Coronavirus Disease-19. OAMJMS. 2020; 8(T1):129-133. https://doi.org/10.3889/oamjms.2020.4954.

7. Naresh B. A Review of the 2019 Novel Coronavirus (COVID-19) Pandemic. Asian J. Pharm. Res. 2020; 10(3):233-238.

8. Nikhat F, Thouheed A, and Moid A. Sars-CoV-2leader-RNA-primed Transcription and RNA-Splicing prevention, control and Treatment. Asian J. Research Chem. 2020; 13(4):291-298.

9. Abdul Kader M. An Extensive Review of Health and Economy of Bangladesh amid Covid-19 Pandemic. Int. J. Rev. and Res. Social Sci. 2020; 8(2): 108-117.

10. Akshay Y, and Shrinivas M. A Novel Approach for Treatment of COVID-19 with Convalescent Plasma. Res. J. Pharma. Dosage Forms and Tech. 2020; 12(3): 227-230.

11. Pankaj S, Pankaj M, Pushpendra K, and Himanshu J. Turmeric: Plant Immunobooster against COVID-19. Res. J. Pharmacognosy and Phytochem. 2020; 12(3): 174-177.

12. Paresh A, Patil, and Ritik. J. Theoretical Study and treatment of Novel COVID-19. Res. J. Pharmacology and Pharmacodynamics. 2020; 12(2): 71-72.

13. Sarfaraz A, Ambreen S, Sajid A, Sarfaraz A, Nawazish A, Maksood A, Ali M, Ayaz A, Salahuddin A, and Mohammad A. Epidemiology, risk, myths, pharmacotherapeutic management and socioeconomic burden due to novel COVID-19: A recent update. Research J. Pharm. and Tech. 2020; 13(9):4435-4442.

Received on 30.09.2020 Modified on 20.02.2021

Asian J. Res. Pharm. Sci. 2021; 11(3):193-194.

DOI: 10.52711/2231-5659.2021.00030